Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Vasomotor and genitourinary symptoms

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Flushes and urinary symptoms can mislead

Chest pain, syncope, focal neurology, sepsis, pyelonephritis, urinary retention, visible haematuria or postmenopausal bleeding requires urgent assessment rather than symptom treatment for menopause.

Action: Record observations, test urine or pregnancy where relevant, examine the suspected system, and use emergency, urology, infection or gynaecological referral pathways before offering routine menopausal therapy.

Synopsis

Recognise vasomotor and genitourinary manifestations of menopause, distinguish important mimics, and match systemic, local and non-hormonal treatment to the symptom domain and cancer history.

  • Vasomotor symptoms are episodic hot flushes and night sweats caused by altered thermoregulation; document frequency, severity, sleep disruption and functional effect rather than relying on their presence alone.
  • Genitourinary syndrome of menopause includes dryness, burning, irritation, reduced lubrication, superficial dyspareunia, urinary urgency, dysuria and recurrent urinary infection arising from oestrogen-sensitive tissue change.
  • Offer systemic HRT for troublesome vasomotor symptoms when suitable, and consider menopause-specific CBT alongside HRT or when hormones are contraindicated or not preferred.
  • Offer vaginal oestrogen for genitourinary symptoms even when systemic HRT is already used; systemic treatment does not reliably restore local vaginal and urinary tissues.
  • Explain that low-dose vaginal oestrogen has minimal systemic absorption, serious adverse effects are very rare and symptoms commonly return if effective treatment is stopped.
  • Non-hormonal moisturisers provide regular background hydration while lubricants reduce friction during sexual activity; either can accompany vaginal oestrogen.
  • After non-hormonal measures fail in someone with previous breast cancer, vaginal oestrogen may be considered; involve the breast specialist when an aromatase inhibitor is being taken.
  • Consider vaginal prasterone after vaginal oestrogen or non-hormonal local treatment is ineffective or not tolerated, and oral ospemifene only when local application is impractical.

Key red flags

A hot episode with chest pain, collapse, sustained arrhythmia, focal neurological deficit or severe breathlessness requires acute cardiovascular or neurological assessment.

Fever, rigors, flank pain, vomiting, hypotension or confusion with urinary symptoms suggests upper urinary infection or sepsis and needs same-day treatment.

Visible haematuria, recurrent culture-negative dysuria, a bladder mass, urinary retention or unexplained weight loss warrants investigation beyond genitourinary syndrome of menopause.

Postmenopausal bleeding, blood-stained discharge, vulval ulceration or a cervical lesion requires a dedicated cancer-exclusion pathway.

Abrupt drenching sweats with fever, lymphadenopathy, tremor, diarrhoea, marked weight loss or new medication exposure suggests infection, malignancy, thyrotoxicosis or a drug effect.

Investigation priorities

01
Symptom and impact diaryFirst step

Quantify hot-flush frequency, night waking, triggers and response to an intervention over time.

Management branches

PhenotypeSeparate systemic and local domains

A person reports flushes, sweats, vaginal discomfort or urinary change around menopause.

  1. Characterise vasomotor episodes and their functional effect separately from vulvovaginal, sexual and urinary symptoms.
  2. Look for systemic, infectious, dermatological, urological and bleeding red flags and examine when findings would change management.
  3. Agree which symptom matters most to the person, because systemic and local treatments answer different problems.

Key medicines

Estradiol 10 microgram vaginal tabletInsert one 10 microgram tablet vaginally each day for two weeks, then insert one tablet twice weekly.Treat active vaginal infection first, investigate unexplained bleeding, review response and use breast-specialist discussion when required by cancer history or aromatase-inhibitor therapy.
Prasterone vaginal pessaryInsert one 6.5 mg pessary into the vagina at bedtime every night and reassess benefit regularly.Contraindications include unexplained bleeding, known, past or suspected breast cancer, oestrogen-dependent malignancy, untreated endometrial hyperplasia and current or previous venous thromboembolism. Review benefit and risk at least every six months; concomitant vaginal oestrogen or systemic hormone treatment is not recommended by the SmPC.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG23 menopause recommendations
  • NICE genitourinary menopause visual summary
  • Estradiol 10 microgram vaginal tablet SmPC
  • Intrarosa prasterone pessary SmPC
  • Senshio ospemifene SmPC

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom